The estimated Net Worth of Christopher I Wright is at least $58.2 mil dollars as of 29 June 2024. Christopher Wright owns over 6,104 units of Cyclerion Therapeutics stock worth over $47,722 and over the last 4 years Christopher sold CYCN stock worth over $10,522.
Christopher has made over 5 trades of the Cyclerion Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Christopher exercised 6,104 units of CYCN stock worth $18,343 on 29 June 2024.
The largest trade Christopher's ever made was exercising 6,104 units of Cyclerion Therapeutics stock on 29 June 2024 worth over $18,343. On average, Christopher trades about 2,401 units every 136 days since 2021. As of 29 June 2024 Christopher still owns at least 15,881 units of Cyclerion Therapeutics stock.
You can see the complete history of Christopher Wright stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN, , 4 Ireland.
Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie, eTerrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics executives and other stock owners filed with the SEC include: